NANOBIOTIX To Present Of new Data From Phase 1 Immunotherapy Program At The 2024 ASCO Annual Meeting Followed By An Investor Conference Call
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix (NASDAQ:NBTX) will present new data from its Phase 1 immunotherapy program at the 2024 ASCO Annual Meeting. The data, from Study 1100 evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer, will be presented by Dr. Colette Shen. An investor event will follow the presentation.
May 28, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanobiotix will present new data from its Phase 1 study on NBTXR3 at the 2024 ASCO Annual Meeting, followed by an investor event. This could generate significant interest and potentially impact the stock price positively.
The presentation of new data at a major oncology conference like ASCO can attract significant attention from investors and analysts. The follow-up investor event suggests that the company expects the data to be well-received, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100